Immunethep Immunethep

Portugal Ventures invests in Immunethep

April 2015

PRESS RELEASE

Immunethep has successfully closed its first round of funding from Portugal Ventures through its fund “Fundo de Capital de Risco Portugal Ventures Biocant”.
“Getting this first round of investment 7 months after we licensed the patent from the University of Porto represents a very important milestone and assures that Immunethep is right on track to start planning for clinical trials” says Bruno Santos, CEO.

By continuing to browse this website, the user accepts the use of cookies that are intended to improve the functioning of the website and to optimize their browsing experience. For more information see our

Accept
Cookie Configuration